Second-Generation Antipsychotics (SGAs)
Similarly to FGAs, SGAs have their mode of action on D2 receptor antagonists as well as 5-HT2A (Serotonin) receptors. SGAs have a higher affinity for 5-HT2A (Serotonin) receptors than D2 receptors, thereby exhibiting fewer extrapyramidal side effects. However, compared with FGAs, SGAs’ have a higher risk of metabolic side effects leading to metabolic syndrome. This can lead to increased risk of HTN, diabetes and cardiovascular complications.

Source: Adapted from: National Health Service. Metabolic syndrome [internet]. 2019 [cited 2022 July 15]. Available from: https://www.nhs.uk/conditions/metabolic-syndrome/
| Individual risks of Antipsychotics | |
| First generation antipsychotics | Second generation antipsychotics |
| Phenothiazine:
e.g. chlorpromazine, promazine, trifluoperazine (drowsiness, dry mouth ++) Butyrophenones: e.g. haloperidol (Tardive Dyskinesia +) Thioxanthenes: Flupenthixol, zuclopenthixol, clopenthixol Higher rates of Extrapyramidal side effects |
Olanzapine (Weight gain ++)
Risperidone (hyperprolactinaemia ++) Paliperidone (hyperprolactinaemia ++) Aripiprazole (low doses can be used to lower prolactin levels) Quetiapine (weight gain ++) Amisulpride (hyperprolactinaemia ++) Clozapine (agranulocytosis ++) High risk of metabolic syndrome |
Source: Adapted from: National Institute for Health and Care Excellence. Psychoses and related disorders [internet]. [cited 2022 July 15]. Available from: https://bnf.nice.org.uk/treatment-summaries/psychoses-and-related-disorders/
Take your subscriptions with you
Our mobile app allows you to access your interview and exam question banks wherever you are.